News >

Expert Highlights Expanding Options for HER2+ Breast Cancer

Danielle Bucco
Published: Monday, Nov 27, 2017

Lajos Pusztai, MD

Lajos Pusztai, MD
Additional treatment options are emerging for patients with HER2-positive breast cancer, according to Lajos Pusztai, MD.

, Pusztai, a professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discussed neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.

OncLive: What data do we have supporting neoadjuvant therapy for patients with HER2-positive breast cancer?

Pusztai: HER2-positive disease has become rich in treatment options, which sometimes creates confusion with how to best select treatments for patients. In the neoadjuvant setting, combining trastuzumab, pertuzumab (Perjeta), and a third-generation chemotherapy of paclitaxel followed by doxorubicin hydrochloride (Adriamycin) and cyclophosphamide (AC) or AC followed by paclitaxel and either of the targeted therapies, produces pathologic complete response (pCR) rates of 75% to 80% in the estrogen receptor (ER)-negative subset and 50% to 60% in the ER-positive subset. Current therapies can accomplish high pCR rates. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication
x